Constipation Drug Induced Clinical Trial
Official title:
Methylnaltrexone Versus Naloxegol in the Treatment of Opioid-Induced Constipation in the Emergency Department
The purpose of this study is to compare the efficacy of subcutaneous versus oral mu-opioid receptor antagonist therapy in opioid induced constipation that is refractory to other bowel regimens.
Opioid-induced constipation can lead to serious complications, including small bowel obstruction, fecal impaction, and bowel perforation. Not only are the medical complications potentially severe, patient quality of life can also be impacted. Two agents are currently available for opioid-induced constipation - oral and subcutaneous methylnaltrexone and oral naloxegol. Mechanistically, both agents antagonize the peripheral mu-opioid receptor in the gastrointestinal tract to decrease constipation without reversing the systemic analgesic effects of opiates. The literature currently available has evaluated the effectiveness of each agent, not the comparative effectiveness of these agents. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04294550 -
Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol
|
||
| Recruiting |
NCT03316859 -
Naloxegol and Opioid-induced Constipation
|
Phase 2/Phase 3 | |
| Completed |
NCT02737059 -
Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT02958566 -
Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery
|
Phase 4 | |
| Recruiting |
NCT04876508 -
The Efficacy of Acupressure in Managing Opioid-induced Constipation
|
N/A | |
| Completed |
NCT04462211 -
Constipation Bundle/Protocol and the Effect of Adherence in the Incidence of Constipation in Critically Ill Patients
|
N/A |